Improved therapeutic activity of HER2 Affibody-targeted cisplatin liposomes in HER2-expressing breast tumor models

Abstract

Affibody-targeting endowed cisplatin liposomes with significantly enhanced, albeit modest, therapeutic activity in HER2-overexpressing tumor model; however, further values are yet to be determined to advance clinical translation of these targeted nanoparticulates.

References

Page 1

	Year	Citations
Phosphorus Assay in Column Chromatography Grant R. Bartlett Journal of Biological Chemistry Phosphorus AssayBiochemistryAnalytical ChemistryLiquid ChromatographyChromatographic Analysis	1959	12.8K
Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2 Dennis J. Slamon, Brian Leyland‐Jones, Steven Shak, New England Journal of Medicine	2001	11.4K
Multinational Study of the Efficacy and Safety of Humanized Anti-HER2 Monoclonal Antibody in Women Who Have HER2-Overexpressing Metastatic Breast Cancer That Has Progressed After Chemotherapy for Metastatic Disease Melody Cobleigh, Charles L. Vogel, Debu Tripathy, Journal of Clinical Oncology	1999	2.8K
Pharmacokinetics of stealth versus conventional liposomes: effect of dose Theresa M. Allen, Cecilie Cetti Hansen Biochimica et Biophysica Acta (BBA) - Biomembranes MedicineConventional LiposomesLipid MovementPharmacologyPharmacokinetics	1991	570
Tumor Imaging Using a Picomolar Affinity HER2 Binding Affibody Molecule Anna Orlova, Mikaela Magnusson, Tove Eriksson, Cancer Research	2006	555
Preparation and characterization of porous hollow silica nanoparticles for drug delivery application Jian‐Feng Chen, Jie‐Xin Wang, Lei Shao Biomaterials NanoparticlesMolecular SieveChemical EngineeringEngineeringNanoporous Material	2003	516
Sterically Stabilized Anti-HER2 Immunoliposomes: Design and Targeting to Human Breast Cancer Cells <i>in Vitro</i> Dmitri B. Kirpotin, John W. Park, Keelung Hong, Biochemistry Proteinlipid InteractionBreast OncologyPeg SpacerEngineeringImmunotherapeutics	1997	439
Antibody to HER-2/neu receptor blocks DNA repair after cisplatin in human breast and ovarian cancer cells. Richard J. Pietras, B M Fendly, V R Chazin, PubMed	1994	438
Tumor targeting using anti-her2 immunoliposomes J.W. Park, Dmitri B. Kirpotin, Keelung Hong, Journal of Controlled Release ImmunologyAnti-her2 ImmunoliposomesAnti-cancer AgentTumor TargetingTargeted Therapy	2001	330
Insertion of poly(ethylene glycol) derivatized phospholipid into pre‐formed liposomes results in prolonged in vivo circulation time Paul S. Uster, Theresa M. Allen, Barbra E. Daniel, FEBS Letters	1996	300

Page 1